Yen-han Tseng

TPQ, Taiwan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 45 publications

Inhaled 3% hypertonic saline is associated with improved symptoms and microbiological stabilisation in antibiotic-naïve nontuberculous mycobacterial lung disease: A prospective study.

Inhaled 3% hypertonic saline is associated with improved symptoms and microbiological stabilisation in antibiotic-naïve nontuberculous mycobacterial lung disease: A prospective study.

Journal: Pulmonology

Published: July 20, 2026

EGFR-Mutant Non-Small Cell Lung Cancer With Small Cell Transformation: Clinicopathological Features, Treatment Landscape, and Biomarker Profiles.

EGFR-Mutant Non-Small Cell Lung Cancer With Small Cell Transformation: Clinicopathological Features, Treatment Landscape, and Biomarker Profiles.

Journal: JTO clinical and research reports

Published: March 28, 2026

First-line immune checkpoint inhibitors plus chemotherapy in Taiwanese patients with extensive-stage small-cell lung cancer.

First-line immune checkpoint inhibitors plus chemotherapy in Taiwanese patients with extensive-stage small-cell lung cancer.

Journal: Journal of the Chinese Medical Association : JCMA

Published: July 03, 2025

Correction: Utilizing TP53 hotspot mutations as effective predictors of gemcitabine treatment outcome in non-small-cell lung cancer.

Correction: Utilizing TP53 hotspot mutations as effective predictors of gemcitabine treatment outcome in non-small-cell lung cancer.

Journal: Cell death discovery

Published: April 25, 2025

The role of immunotherapy and chemotherapy combinations in TKI-resistant EGFR-mutant non-small cell lung cancer: insights from real-world evidence.

The role of immunotherapy and chemotherapy combinations in TKI-resistant EGFR-mutant non-small cell lung cancer: insights from real-world evidence.

Journal: American journal of cancer research

Published: March 19, 2025

Real-world therapeutic strategies and survival outcomes in advanced HER2 -mutant non-small cell lung cancer.

Real-world therapeutic strategies and survival outcomes in advanced HER2 -mutant non-small cell lung cancer.

Journal: Journal of the Chinese Medical Association : JCMA

Published: January 27, 2025

Recurrence of tuberculosis and associated risk factors among Non-HIV patients in Taiwan: A retrospective cohort study.

Recurrence of tuberculosis and associated risk factors among Non-HIV patients in Taiwan: A retrospective cohort study.

Journal: Journal of infection and public health

Published: January 15, 2025

Treatment patterns and survival outcomes in patients with small-cell lung cancer following failure of first-line platinum-based chemotherapy.

Treatment patterns and survival outcomes in patients with small-cell lung cancer following failure of first-line platinum-based chemotherapy.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: December 28, 2024

Reduced host cell-free DNA as a biomarker in latent tuberculosis infection among tuberculosis contacts.

Reduced host cell-free DNA as a biomarker in latent tuberculosis infection among tuberculosis contacts.

Journal: Tuberculosis (Edinburgh, Scotland)

Published: December 12, 2024

Microbiological aspects and clinical impact of lower lung field tuberculosis: An observational cohort study in Peru.

Microbiological aspects and clinical impact of lower lung field tuberculosis: An observational cohort study in Peru.

Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

Published: September 04, 2024

Chest Radiograph Screening for Detecting Subclinical Tuberculosis in Asymptomatic Household Contacts, Peru.

Chest Radiograph Screening for Detecting Subclinical Tuberculosis in Asymptomatic Household Contacts, Peru.

Journal: Emerging infectious diseases

Published: May 23, 2024

Utilizing TP53 hotspot mutations as effective predictors of gemcitabine treatment outcome in non-small-cell lung cancer.

Utilizing TP53 hotspot mutations as effective predictors of gemcitabine treatment outcome in non-small-cell lung cancer.

Journal: Cell death discovery

Published: March 27, 2024

Showing 1-12 of 45

Last Updated: 09/26/2026